IRIS
STORTI, Paola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.342
AS - Asia 3.713
EU - Europa 3.005
SA - Sud America 477
AF - Africa 191
Continente sconosciuto - Info sul continente non disponibili 11
OC - Oceania 3
Totale 11.742
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.207
SG - Singapore 1.505
CN - Cina 1.308
SE - Svezia 546
IE - Irlanda 502
FI - Finlandia 456
DE - Germania 418
IT - Italia 375
BR - Brasile 372
HK - Hong Kong 283
VN - Vietnam 199
TR - Turchia 164
NL - Olanda 125
ZA - Sudafrica 116
CA - Canada 93
FR - Francia 91
UA - Ucraina 85
GB - Regno Unito 77
RU - Federazione Russa 76
AT - Austria 68
IN - India 54
AR - Argentina 45
CI - Costa d'Avorio 42
RO - Romania 37
BD - Bangladesh 36
CZ - Repubblica Ceca 34
BE - Belgio 33
JP - Giappone 32
MX - Messico 25
PL - Polonia 21
EC - Ecuador 18
ES - Italia 16
IQ - Iraq 15
KR - Corea 13
PK - Pakistan 13
UZ - Uzbekistan 13
LT - Lituania 12
CO - Colombia 11
ID - Indonesia 11
AE - Emirati Arabi Uniti 10
EU - Europa 9
KZ - Kazakistan 7
PY - Paraguay 7
VE - Venezuela 7
BG - Bulgaria 6
CL - Cile 6
IR - Iran 6
KE - Kenya 6
UY - Uruguay 5
BO - Bolivia 4
IL - Israele 4
MA - Marocco 4
PH - Filippine 4
QA - Qatar 4
SA - Arabia Saudita 4
CH - Svizzera 3
ET - Etiopia 3
KH - Cambogia 3
LV - Lettonia 3
MY - Malesia 3
NG - Nigeria 3
OM - Oman 3
PA - Panama 3
PT - Portogallo 3
SN - Senegal 3
AO - Angola 2
AU - Australia 2
CM - Camerun 2
CR - Costa Rica 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
EE - Estonia 2
EG - Egitto 2
GD - Grenada 2
HU - Ungheria 2
JO - Giordania 2
KG - Kirghizistan 2
LU - Lussemburgo 2
MD - Moldavia 2
PE - Perù 2
PS - Palestinian Territory 2
RS - Serbia 2
SC - Seychelles 2
SM - San Marino 2
TN - Tunisia 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AL - Albania 1
AZ - Azerbaigian 1
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
BZ - Belize 1
CY - Cipro 1
DM - Dominica 1
GA - Gabon 1
GT - Guatemala 1
HN - Honduras 1
Totale 11.728
Salva come PNG Salva come JPEG
Città #
Singapore 780
Ashburn 540
Chandler 538
Dublin 500
Beijing 340
Santa Clara 339
Dallas 324
Hong Kong 280
Munich 198
Parma 172
Jacksonville 159
Boardman 155
Ann Arbor 145
Izmir 138
Nanjing 135
Los Angeles 130
Dearborn 125
New York 124
Shanghai 119
Johannesburg 109
Princeton 90
Ho Chi Minh City 82
Helsinki 78
Hefei 67
Vienna 63
San Mateo 62
Kunming 58
Shenyang 52
Toronto 52
Wilmington 50
São Paulo 45
Marseille 43
Abidjan 42
Buffalo 41
Columbus 41
Düsseldorf 41
Moscow 39
Nanchang 38
Hanoi 36
Turku 35
Hebei 34
Jinan 34
Tianjin 34
Brussels 32
Jiaxing 32
Tokyo 31
Bremen 29
Brno 27
Houston 24
Des Moines 23
Changsha 22
Focsani 22
Milan 20
The Dalles 20
Warsaw 19
Council Bluffs 18
Seattle 18
Atlanta 17
Brooklyn 17
Orem 17
Bologna 16
Chicago 16
Denver 16
Frankfurt am Main 16
Guangzhou 16
Hangzhou 16
Montreal 16
Poplar 16
Pune 16
Stockholm 16
Kocaeli 15
London 15
Phoenix 15
Zhengzhou 15
Woodbridge 14
Norwalk 13
Rome 13
Seoul 13
Boston 12
Redmond 12
Tashkent 12
Nuremberg 11
Amsterdam 10
Chennai 10
San Francisco 10
Chengdu 9
Chongqing 9
Jesi 9
Taizhou 9
Ankara 8
Fuzhou 8
Haiphong 8
Jakarta 8
Ninh Bình 8
Rio de Janeiro 8
Dhaka 7
Dubai 7
Porto Alegre 7
Ahmedabad 6
Baghdad 6
Totale 7.362
Salva come PNG Salva come JPEG
Nome #
Comet assay and prediction of clinical outcome after DNA-damaging drugs treatment 238
Are the Myeloma bone microevironment cells tumoral or not? 195
Ammonium Production and Glutamine-Addiction of Myeloma Cells: New Attractive Targets in Multiple Myeloma 193
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target 181
Bone marrow CX3CL1/Fractalkine is a new player of the pro-angiogenic microenvironment in multiple myeloma patients 179
Neurofibromatosis type I and multiple myeloma coexistence: A possible link? 172
HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients 165
Application of next-generation sequencing for the genomic characterization of patients with smoldering myeloma 162
CD14+CD16+ monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy 162
Hypoxia and Hypoxia Inducible Factor (HIF)-1{alpha} in Multiple Myeloma: Effect on the Pro-Angiogenic Signature of Myeloma Cells and the Bone Marrow Microenvironment 161
Novel targets for the treatment of relapsing multiple myeloma 161
CC-4047 (Pomalidomide) inhibits multiple myeloma-induced osteoclast formation targeting RANKL in the bone marrow microenvironment 159
Hypoxia-Inducible Factor (HIF)-1 alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo 158
Activation of non-canonical wnt pathway in human mesenchymal cells affects osteogenic differentiation: a potential target in Multiple Myeloma microenvironment 156
Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma 156
HOXB7 is a key gene involved in Myeloma cell growth and Myeloma-induced angiogenesis in Multiple Myeloma patients 152
Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy 148
Hypoxia and hypoxia inducible factor (HIF)-1α in Multiple Myeloma patients: role in the angiogenic switch 148
The Immunomodulatory drugs Lenalidomide and Pomalidomide inhibit multiple myeloma-induced osteoclast formation and RANKL/OPG ratio in myeloma microenvironment targeting the expression of adhesion molecules 146
Oxygen tension in the bone marrow (BM) of patients with malignant and indolent monoclonal gammopathy: role of hypoxia and hypoxia-inducible factor (HIF)-1{alpha} in the regulation of gene expression and pro-angiogenic profiles of CD138+ cells 143
Role of 1q21 in multiple myeloma: From pathogenesis to possible therapeutic targets 142
A Mouse Model of Telomere Dysfunction Recapitulates Hallmark Features of Human Myelodysplastic Syndrome 140
Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells 139
HOXB7 is critically involved in Multiple Myeloma-induced angiogenic switch 138
The homeobox gene HOXB7 regulates the production of pro-angiogenic molecole by myeloma cells and it is a target in myeloma-induced angiogenesis 137
Myeloma cells inhibit the non-canonical wnt co-receptor ror2 in human mesenchymal/osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on mm-induced impairment of the osteogenic differentiation process 136
The IMID CC-4047 (Pomalidomide) inhibits myeloma-induced osteoclast formation 134
LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION MODULATING BOTH MONOCYTE DIFFERENTIATION AND MESENCHYMAL STROMAL CELL INHIBITORY PROPERTIES 134
Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin? 132
DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY 131
Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo 131
ILF2-YB1 Protein Interaction Modulates RNA Splicing to Induce Resistance to Chemotherapy in High Risk Multiple Myeloma 130
Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability 130
In vitro and In vivo evidences of osteocytes involvement in myeloma-induced osteolysis 129
Galectin-1 Is Highly Expressed By Myeloma Cells and the Bone Marrow Microenvironment and Its Suppression Delineates a New Therapeutic in Vitro and in Vivo Strategy in Multiple Myeloma 128
Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity 128
IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts 126
Follow-up of humoral and cellular immune responses after the third SARS-CoV-2 vaccine dose in multiple myeloma patients 125
The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells 124
PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients 124
Bone marrow CD14+ cells show different transcriptional profiles in Multiple Myeloma (MM) as compared to smoldering MM and MGUS: overexpression of IL21R and its involvement in osteoclastogenesis 123
Identification of PSMB4 and PSMD4 as novel target genes correlated with 1q21 amplification in patients with smoldering myeloma and multiple myeloma 122
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties 122
Non canonical wnt signal pathway (Wnt5a/ror2) activation stimulates the osteogenic differentiation process of bone mesenchymal cells being a potential target in multiple myeloma bone disease 121
Bone marrow monocyte / macrophage derived activin a mediates the osteoclastogenic effects of IL-3 in myeloma 121
Telomere Dysfunction Drives Aberrant Hematopoietic Differentiation and Myelodysplastic Syndrome 120
Increased osteocyte apoptosis in Multiple Myeloma patients: a potential role in bone remodeling alterations related to osteolytic bone lesions 119
Angiogenesis and multiple myeloma 118
CC-Chemokine Ligand 20/Macrophage Inflammatory Protein-3A and CC-Chemokine Receptor 6 Are Overexpressed in Myeloma Microenvironment Related to Osteolytic Bone Lesions 117
Modulation of non canonical wnt5a/ror2 signaling pathway in human mesenchymal cells increases osteogenic differentiation counterbalancing the effect of myeloma cells 117
Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation 116
Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma 116
Possible targets to treat myeloma-related osteoclastogenesis 115
Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients 114
Bone microenvironment cells show a different pattern of gene expression profiling in relationship with the presence of osteolytic bone lesions in Multiple Myeloma patients 114
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma 114
A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors 113
The anti-myeloma effect of Lenalidomide is increased by hypoxia-inducible factor (HIF)-1a inhibition in multiple myeloma cells both in vitro and in vivo 113
Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma 111
Oncolytic Virotherapy in Multiple Myeloma: A Possible Alternative Role of Bovine Viruses 110
Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies 105
ILF2-YB1 INTERACTION MODULATES RNA SPLICING TO INDUCE RESISTANCE TO DNA-DAMAGING AGENTS IN 1Q21-AMPLIFIED MULTIPLE MYELOMA 105
The impact of CD56 expression in smoldering myeloma patients on early progression 104
The activation of wnt5a-mediated non canonical wnt signaling in human bone marrow osteoprogenitor cells increases osteoblastogenesis and counterbalances the inhibitory effect of myeloma cells on ror2/fzd5 expression 104
Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma 104
CD38 expression by plasma cells in extramedullary multiple myeloma 103
Il mieloma multiplo nell'era dei nuovi farmaci. Patogenesi 102
Trascriptome Analysis of Bone Marrow CD14+ Monocytes Revealed Differential Expression Profiles in Symptomatic Multiple Myeloma (MM) Compared to Smoldering MM and Monoclonal Gammopathy of Undetermined Significance 102
ASSESSMENT OF THE INTERLABORATORY VARIABILITY AND ROBUSTNESS OF JAK2V617F MUTATION ASSAYS: A STANDARDIZATION STUDY INVOLVING A CONSORTIUM OF 19 ITALIAN LABORATORIES 102
Hypoxia-inducible factor (HIF)-1 is a therapeutic target in myeloma-induced angiogenesis and bone destruction in vitro and in vivo 100
PD-L1/PD-1 axis in multiple myeloma microenvironment and a possible link with CD38-mediated immune-suppression 98
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma 96
Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with Multiple Myeloma bone disease 95
Relationship between bone imaging features and bone marrow cytokine and chemokine profiles in patients with monoclonal gammopathy 93
Hypoxia-Inducible Factor (HIF)-1a Is A Therapeutic Target in Myeloma-Induced Angiogenesis and Bone Destruction in Vivo 93
Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations 92
Overexpression of Pro-Osteoclastogenic Cytokine Receptors and Chemokines By Bone Marrow CD14(+) Monocytes of Multiple Myeloma (MM) Patients As Compared to Smoldering MM (SMM) and Monoclonal Gammopathy of Uncertain Significance (MGUS): Role of Interleukin(IL)-21 Receptor/IL-21 Axis in MM-Induced Osteoclastogenesis 89
Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma 88
Transcriptional and proteomic profiles of bone marrow CD14+ cells in multiple myeloma (MM) compared to smoldering MM and MGUS: overexpression of Interleukin (IL)-21 receptor and its involvement in MM-induced osteoclastogenesis 87
Oncolytic viruses: a potential breakthrough immunotherapy for multiple myeloma patients 86
Relationship between skeletal involvement, cytogenetic features and bone marrow profiles of cytokines and chemokines in patients with monoclonal gammopathy 86
Role of Galectins in Multiple Myeloma. 84
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response 83
MYELOMA CELLS FROM THE BONE MARROW TO THE SKIN: HOW? 83
The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide 83
Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction 82
Interleukin-3 induces activin A in bone marrow monocytes: role in multiple myeloma patients 81
Monoclonal anti-CD38 therapy in human myeloma: retrospects and prospects 80
Molecular Features of the Mesenchymal and Osteoblastic Cells in Multiple Myeloma 80
Relationship between presence of osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: role of chemokine (C-C motif) ligand 20 80
The Myeloma Cells Escape from Bone Marrow to Skin Extramedullary Localization upon Bortezomib Resistance: Role of CXCR4 79
IL3 Induces Osteoclastogenesis In Vivo and Is Modulated By Bone Marrow Monocyte / Macrophage Derived Activin A 78
Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules 78
Loss of stromal galectin-1 enhances multiple myeloma development: Emphasis on a role in osteoclasts 77
Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells 76
Hypoxia-Inducible Factor (HIF)-1α Is a Therapeutic Target in Myeloma-Induced Angiogenesis 72
Is there a way to predict the clinical outcome of DNA strand breaks generating drugs? The case of calicheamicin 69
Metabolic features of myeloma cells in the context of bone microenvironment: Implication for the pathophysiology and clinic of myeloma bone disease 68
Detection of DNA strand breaks as individual predictive response to Gemtuzumab Ozogamicin in acute myeloid leukaemia 64
The transcriptomic profile of CD138+ cells from patients with early progression from smoldering to active multiple myeloma remains substantially unchanged 62
Totale 11.802
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.909
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.909
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021288 0 0 0 0 0 10 26 23 110 32 50 37
2021/2022491 14 9 15 42 13 10 67 55 19 42 39 166
2022/20232.037 213 229 152 148 168 227 66 137 599 25 56 17
2023/2024776 30 71 14 19 55 215 77 34 21 46 51 143
2024/20252.663 56 108 133 234 269 278 144 144 354 205 230 508
2025/20263.387 519 470 755 539 872 232 0 0 0 0 0 0
Totale 11.941